[Therapeutic possibilities in terminal heart failure].
The severe and terminal cardiac insufficiency with myogenic failure and severe neurohumoral dysregulation means a problem situation in the chronically progressive or acute form of the course. The medicamentous treatment in form of the basis therapy with glycosides and saluretics may be improved by vasodilators or/and adrenergic agonists. In most cases we succeed in stabilizing the cardiovascular situation once to several times. As a rule the maximum stress only little increases. The neurohumoral dysregulation remains in different form apart from the basic disease which is no more to be corrected. Thus, in principle the vicious circle is closed. Whether the group of the so-called new inotropic and vasodilating pharmaca may essentially change the prognosis due to better influences on cardial and vascular and neurohumoral, respectively, dysfunctions, is not yet to be answered. A distinct alternative from the aspect of the cardiovascular function gives only the cardiac transplantation. The artificial heart and ventricular assist-systems, respectively, are accepted for the bridging-over up to the cardiac transplantation. The hitherto existing state of development does not yet correspond to the imaginations of a pump regulated according to the needs, disregarding material, coagulation and energy problems.
Urbaszek
W
W
Klinik für Innere Medizin, Bereich Medizin der Wilhelm-Pieck-Universität Rostock.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D014665:Vasodilator Agents / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D002316:Cardiotonic Agents; D004232:Diuretics; D014665:Vasodilator Agents
Therapeutische Möglichkeiten bei terminaler Herzinsuffizienz.